Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study

P. Xing, X. Zheng, Y. Wang,T. Chu,S. Wang, J. Jiang,J. Qian, X. Han, L. Ding, Y. Wang, L. Cui,H. Li,L. Li,X. Chen, B. Han,P. Hu,Y. Shi

ESMO Open（2022）

引用 0|浏览0

暂无评分

摘要

•BPI-15086 is safe and has partial effectiveness in patients with advanced T790M+ NSCLC after previous EGFR-TKI therapy.•A different safety profile for BPI-15086 compared with other third-generation EGFR-TKIs.•The modest efficacy in this study is still deemed important and should be added to the literature of third-generation TKIs.

查看译文

关键词

epidermal growth factor receptor,NSCLC,tyrosine kinase inhibitor,third generation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要